Top UK Facility Achieves Funding Success
Scientists plan to use the funds to repurpose Artesunate, an antimalarial drug discovered by Nobel Prize Laureate (2015) in a clinical trial aimed at cutting the rate of metastases in colorectal cancer.
Clinical researchers at St George’s, University of London, U.K. have used crowd-funding methods based on donations and rewards to raise cash for a Phase II trial in 140 bowel cancer patients on the FutSci platform.
The campaign has reached its target of £50,000 (approximately $75K) in the first 45 days, according to Dr Deepika Kassen, PhD, Director of FutSci. To date it has been backed by 320 people from 16 countries and has raised £53,088.88 ($80564.76). There are still 10 days left of the campaign.
Scientists plan to use the funds to repurpose Artesunate, an antimalarial drug discovered by Nobel Prize Laureate (2015) Tu Youyou, in a clinical trial aimed at cutting the rate of metastases in colorectal cancer.
The campaign is a collaboration between the researchers, FutSci, Bowel Disease UK and the Anticancer Fund. The researchers are using the money to top-up funds they already have from charity. Budget cuts mean the research is not funded by government/institutional bodies, and the pharmaceutical industry is not interested because it is a relatively cheap drug, noted Kassen.
More information is available at www.futsci.com/project/antimalarial-cancer.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
